Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

D. M. Mintzer, D. Kelsen, D. Frimmer, R. Heelan, Richard J. Gralla

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)711-712
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Cisplatin
Mannitol
Malignant Mesothelioma
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mintzer, D. M., Kelsen, D., Frimmer, D., Heelan, R., & Gralla, R. J. (1985). Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treatment Reports, 69(6), 711-712.

Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. / Mintzer, D. M.; Kelsen, D.; Frimmer, D.; Heelan, R.; Gralla, Richard J.

In: Cancer Treatment Reports, Vol. 69, No. 6, 1985, p. 711-712.

Research output: Contribution to journalArticle

Mintzer, DM, Kelsen, D, Frimmer, D, Heelan, R & Gralla, RJ 1985, 'Phase II trial of high-dose cisplatin in patients with malignant mesothelioma', Cancer Treatment Reports, vol. 69, no. 6, pp. 711-712.
Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla RJ. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treatment Reports. 1985;69(6):711-712.
Mintzer, D. M. ; Kelsen, D. ; Frimmer, D. ; Heelan, R. ; Gralla, Richard J. / Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 6. pp. 711-712.
@article{054a0b46b47e44ecb486a81835bbf736,
title = "Phase II trial of high-dose cisplatin in patients with malignant mesothelioma",
abstract = "Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13{\%}; 95{\%} confidence limits, 4{\%}-31{\%}) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.",
author = "Mintzer, {D. M.} and D. Kelsen and D. Frimmer and R. Heelan and Gralla, {Richard J.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "711--712",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

AU - Mintzer, D. M.

AU - Kelsen, D.

AU - Frimmer, D.

AU - Heelan, R.

AU - Gralla, Richard J.

PY - 1985

Y1 - 1985

N2 - Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

AB - Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0021885946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021885946&partnerID=8YFLogxK

M3 - Article

C2 - 4040424

AN - SCOPUS:0021885946

VL - 69

SP - 711

EP - 712

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -